Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.64 |
| ▸ | L3MBTL1 | Q9Y468 | 6/20 | 0.50 |
| ▸ | MAPT | P10636 | 4/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | GLA | P06280 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31655455 | 0.91 | ALDH1A1 (0.55) | ALDH1A1L3MBTL1MAPTNPSR1KDM4E | |
| SCHEMBL11354404 | 0.91 | ALDH1A1 (0.55) | ALDH1A1L3MBTL1MAPTNPSR1KDM4E | |
| SCHEMBL1838872 | 0.89 | ALDH1A1 (0.69) | ALDH1A1L3MBTL1MAPTNPSR1KDM4E | |
| SCHEMBL5404445 | 0.87 | ALDH1A1 (0.55) | ALDH1A1L3MBTL1MAPTNPSR1KDM4E | |
| SCHEMBL20509838 | 0.87 | ALDH1A1 (0.55) | ALDH1A1L3MBTL1MAPTNPSR1KDM4E | |
| SCHEMBL9751766 | 0.85 | ALDH1A1 (0.53) | ALDH1A1L3MBTL1MAPTNPSR1KDM4E | |
| SCHEMBL11139017 | 0.85 | L3MBTL1 (0.56) | ALDH1A1L3MBTL1MAPTNPSR1KDM4E | |
| SCHEMBL3791890 | 0.85 | ALDH1A1 (0.53) | ALDH1A1L3MBTL1MAPTNPSR1KDM4E | |
| SCHEMBL17887304 | 0.85 | L3MBTL1 (0.55) | ALDH1A1L3MBTL1MAPTNPSR1KDM4E | |
| SCHEMBL7928280 | 0.83 | MCHR1 (0.58) | ALDH1A1MAPTKDM4EMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024143473-A1 | DECOMPOSITION INHIBITOR FOR TRANSITION METAL OXIDANTS | 株式会社トクヤマ | 2024-07-04 | — | — | WO | disclosed |
| EP-3390400-B1 | HETEROARYLHYDROXYPYRIMIDINONES AS AGONISTS OF THE APJ RECEPTOR | BRISTOL MYERS SQUIBB CO (US) | 2021-01-20 | — | — | EP | disclosed |
| EP-3390400-B1 | HETEROARYLHYDROXYPYRIMIDINONES AS AGONISTS OF THE APJ RECEPTOR | BRISTOL MYERS SQUIBB CO (US) | 2021-01-20 | — | — | EP | disclosed |
| CN-110114418-B | Azo compound or salt thereof, and dye-based polarizing film and dye-based polarizing plate containing azo compound or salt thereof | 日本化药株式会社 | 2020-09-01 | — | — | CN | disclosed |
| US-10703746-B2 | Mutant IDH1 inhibitors useful for treating cancer | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2020-07-07 | — | — | US | disclosed |
| US-10669261-B2 | Heteroarylhydroxypyrimidinones as agonists of the APJ receptor | Bristl-Myers Squibb Company (US) | 2020-06-02 | — | — | US | disclosed |
| US-10669261-B2 | Heteroarylhydroxypyrimidinones as agonists of the APJ receptor | Bristl-Myers Squibb Company (US) | 2020-06-02 | — | — | US | disclosed |
| US-10251827-B2 | Oxidation dyeing process using a composition comprising a monoaminobenzene and a metal catalyst | L'OREAL (FR) | 2019-04-09 | — | — | US | disclosed |
| US-20180362508-A1 | HETEROARYLHYDROXYPYRIMIDINONES AS AGONISTS OF THE APJ RECEPTOR | BRISTOL MYERS SQUIBB CO (US) | 2018-12-20 | — | — | US | disclosed |
| EP-3390400-A1 | HETEROARYLHYDROXYPYRIMIDINONES AS AGONISTS OF THE APJ RECEPTOR | Bristol-Myers Squibb Company (US) | 2018-10-24 | — | — | EP | disclosed |
| EP-0051792-A1 | Derivatives of hydroxamic-acid esters, process for their preparation and their use as herbicides | BAYER AG (DE) | 1982-05-19 | — | — | EP | disclosed |
| EP-0010715-B1 | N-ALKYL-HALOACETANILIDES SUBSTITUTED BY AN OXIME GROUP, PROCESSES FOR THEIR PREPARATION, HERBICIDAL COMPOSITIONS CONTAINING THEM, A PROCESS FOR COMBATING WEEDS, A PROCESS FOR PREPARING HERBICIDAL COMPOSITIONS. | BAYER AG (DE) | 1982-01-27 | — | — | EP | disclosed |
| US-4295876-A | N-(2,5-Diazolyl)-alkyl-haloacetanilides, compounds and herbicidal compositions | BAYER AKTIENGESELLSCHAFT (DE) | 1981-10-20 | — | — | US | disclosed |
| EP-0024747-A1 | Anilinomethyloxime ethers and processes for their production | BAYER AG (DE) | 1981-03-11 | — | — | EP | disclosed |
| EP-0019742-A2 | N-(2,5-diazolyl) alkyl-haloacetanilides, processes for their preparation and their use as herbicides | BAYER AG (DE) | 1980-12-10 | — | — | EP | disclosed |
| EP-0010715-A1 | N-alkyl-haloacetanilides substituted by an oxime group, processes for their preparation, herbicidal compositions containing them, a process for combating weeds, a process for preparing herbicidal compositions. | BAYER AG (DE) | 1980-05-14 | — | — | EP | disclosed |
| EP-0010163-A1 | N-Diazolylalkyl-chloroacetanilides, process for their preparation and their use as herbicides | BAYER AG (DE) | 1980-04-30 | — | — | EP | disclosed |
| EP-0010166-A1 | N-(1,2-Azolyl)alkyl-chloroacetanilides, process for their preparation and their use as herbicides | BAYER AG (DE) | 1980-04-30 | — | — | EP | disclosed |
| EP-0009693-A1 | N-(1,3-Thiazolyl)-alkyl-chloroacetanilides, process for their preparation and their use as herbicides | BAYER AG (DE) | 1980-04-16 | — | — | EP | disclosed |
| US-4164511-A | Manufacture of N-arylglycinonitriles | BASF AKTIENGESELLSCHAFT (DE) | 1979-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10669261-B2 | Heteroarylhydroxypyrimidinones as agonists of the APJ receptor | APLNR, GPBAR1, AGTR1 | ALDH1A1 912/4885L3MBTL1 4790/4885MAPT 4739/4885 |
| US-10251827-B2 | Oxidation dyeing process using a composition comprising a monoaminobenzene and a metal catalyst | KRT18, CYB5R3, CBR3 | ALDH1A1 444/4885L3MBTL1 4003/4885MAPT 1029/4885 |
| US-20180362508-A1 | HETEROARYLHYDROXYPYRIMIDINONES AS AGONISTS OF THE APJ RECEPTOR | APLNR, GPBAR1, AGTR1 | ALDH1A1 912/4885L3MBTL1 4790/4885MAPT 4739/4885 |
| US-10703746-B2 | Mutant IDH1 inhibitors useful for treating cancer | IDH1, IDH3B, IDH3A | ALDH1A1 417/4885L3MBTL1 2656/4885MAPT 4568/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.